Why the study?
The precise time when to discontinue aspirin remains unresolved amidst emerging evidence on antiplatelet therapies.
This review summarizes the evolving role of aspirin in coronary artery disease, emphasizing the need for further investigation into optimal discontinuation timing and novel delivery methods.
Controversies on aspirin discontinuation timing in CAD persist; leaves open opportunities for novel formulations pending prospective trials.
INTRODUCTION: receptor inhibitor monotherapy. However, the precise time when to discontinue aspirin is still unresolved. AREAS COVERED: Evidence from recent studies evaluating the role of aspirin in primary and secondary prevention studies was collected from a selective literature search. In this review, the authors discuss current recommendations, large-scale studies of aspirin therapy, controversies, and potential future opportunities for aspirin therapy. EXPERT OPINION: receptor inhibitor monotherapy. The potential benefits of novel aspirin formulations and alternative delivery methods, such as inhaled aspirin, are undergoing much-needed investigation with the goal of optimizing care for a wide range of patients.
No takes yet. Share an insight, caveat, or question.
Tantry et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: